Robotic Transjugular Transcatheter Tricuspid Valve Replacement

Recruiting N/A Interventional Study
Tricuspid Regurgitation (TR) Valvular Heart Diseases Transcatheter Valve Replacement
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 90
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
10 (estimated)
Sponsor
Prince of Wales Hospital, Shatin, Hong Kong · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Valvular heart disease (VHD), caused by abnormalities in heart valves, can lead to severe complications such as heart failure and death, with approximately 220 million affected patients worldwide. The prevalence of VHD continues to grow alongside the aging global population. Transcatheter heart valve interventions have emerged as minimally invasive alternatives, offering benefits like shorter reco…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age 18-90 * Severe symptomatic TR * Deem high risk for tricuspid valve surgery determined by a multidisciplinary heart team (including cardiologists, cardiac surgeons and cardiac anesthetists) and * Anatomically feasible for transjugular transcatheter tricuspid valve replaceme…
Contacts

Daniel Xu

852 35051518

xjldaniel@gmail.com

CONTACT